

## The Relationship between Substance Use Disorders and Co-Occurring Mental Health Conditions: Integrated Treatment Approaches

<sup>1</sup>Umama Gulzar, <sup>2</sup>Dr Habiba Jan Qureshi, <sup>3</sup>Faisal Zafar, <sup>4</sup>Dr Muqaddas, <sup>5</sup>Dr Zeeshan Younas

<sup>1</sup>Poonch Medical College Rawlakot AJK

<sup>2</sup>Ajk medical college Muzaffarbad

<sup>3</sup>Farooq Teaching Hospital Islamabad

<sup>4</sup>AJK medical College

<sup>5</sup>AJK medical College, Muzaffarbad

### Abstract

**Background:** Substance Use Disorders (SUDs) plus co-morbid mental health disorders now constitute a major preventable public health catastrophe in human social life and the population. It is also important to recognize that they occur frequently, can affect people of any age and are difficult to treat, which is why integration should be the focus.

**Objectives:** This proposal aims at establishing the correlation between SUDs and other mental illnesses and the impact of combined treatment therapies.

**Methods:** RCT, Meta analysis, Longitudinal, Cross-sectional studies were also used to conduct an extensive review. Demographic characteristics, SUD and mental health conditions' severity, and treatment process results were documented among adults SUD patients and those with co-morbid depression and PTSD. The comparison was made between Integrated Treatment Modalities which include IDDT and CBT with medication management and non-Integrated Treatment Modalities.

**Results:** Again, results obtained from the analyses of both integrated and non-integrated treatments were more favourable toward integrated treatment methods in terms of lowering substance use and mental health symptoms. Highly positive, beneficial results were seen in aspects of patient quality of life, medication compliance, and relapse in cross-sectional and various level of illness populations and people of different demographics.

**Conclusion:** The evidence also reveals that Integrated treatment programs are vital since substance dependence and mental illnesses affect the same persons. This review looks at the comparisons between integrated models as well as points out the importance of patient-centered, affordable treatment. It is therefore advisable for future research to target the effects of the treatment on the patients in the long-term, other treatment regimens and how the existing treatments can be made more accessible to individuals from other ethnic backgrounds.

**Keywords:** Substance Use Disorders, Mental Health Conditions, Integrated Treatment, Cognitive Behavioural Therapy, Dual Diagnosis

### Introduction

Substance use disorders (SUDs) are multifaceted with regard to their diagnosis and indicate the continued use of substances even when such consumption has negative effects. It can include legal drugs/legally addictive substances such as alcohol, prescribed drugs and other legal highs, and the illegal drugs including opiates, stimulants and Ganja. SUDs can be categorized based on the type of substance used: Specifically, the two are alcohol use disorder, opioid use disorder, stimulant use disorder, cannabis use disorder, and other substance use disorders. Each of them has its peculiarities but all of them have common properties, which include development of increased craving for a substance, compulsive use of the substance and the use of the substance despite the occurrence of severe problems resulting from its use. SUDs are diagnosed according to the DSM-5 criteria such as tolerance, withdrawal, and lack of control over substance use [1].

In particular, SUDs are substantially common and pose a great threat to the wellbeing of society. Furthermore, NSDUH also shows that millions of the people in the United States are struggling with the SUDs. The most popular type of disorder is the alcohol use disorder which impacts approximately 14.1 million adults. Opioid use disorder has been a prevalent issue especially with the current opioid

crisis, of this, there are around 2 million people affected. Its use disorder such as cocaine and methamphetamines are also common, which cause a lot of impact on the population health. From the demographic perspective SUDs do not differentiate; they could affect a child, a man or woman, a black or white person, a rich or a poor individual but for certain reasons, intellectually, genetically, environmentally, and socially some bear a higher risk than others [2].

It is crucial to establish that mental health disorders co-occur with SUDs in patients, a situation referred to as dual diagnosis or comorbidity. Such conditions may extent to include depressive cascades, anxiety disorders, post traumatic stress disorders as well as bipolar and mood disorders. Compared to adults who do not have SUDs, depressed patients with SUDs present more severe substance use and treatment process. Mental health conditions such as anxiety disorders such as generalized anxiety disorder, panic disorder, and social anxiety disorder also form a significant comorbidity list with SUDs, where the individual ends up using the substance in a mals adaptive attempt at coping with the anxiety. Another common comorbidity is PTSD, that emerges due to traumatic exposure, and is significant in development of SUDs seen in different population including war veterans and survivors of violence. Bipolar disorder, where patients exhibit both manic and depressive episodes, is another complex comorbidity with SUD because mood and substance-use disorders need to be made stable for coordinated treatment [3].

In the cases of SUDs, it is quite common to find comorbid mental health disorders in the affected persons. Research has found that about half of the people with a SUD meet the criteria of at least one other minimum mental disorder. This high prevalence shows the need to treat the two conditions at the same time since they are closely related. The current state of development, gender, and age, and economic status have an influential impact on the incidence and severity of the co-existing disorders. For instance, young adults or those from the low-income bracket may be more vulnerable to dual diagnosis due to stress, poor health check-up and social setting that encourages the use of substances. Major depression and SUDs are thus not discrete problems but are diseases that converge and have significant effects on people, families, and society. Combined, the two disorders can have longer and more severe consequences for the physical and mental health of individuals and may increase a patient's risk of suicide. Self-medication is the other aspect of this relationship of substance use and mental health symptoms where each condition worsens the other leading to a difficult recovery. Families are also affected greatly, for instance they suffer from mental, financial and social consequences. It results to changes in the dynamics of the family affected, increased level of stress on the family caregiver and economic burden in terms of costs incurred in managing the dual diagnosis as well as productivity loss among caregivers [4].

From the sociological point of view the problem of interacting SUDs and mental health disorders is rather pressing. The economic loss includes all the treatment cost and cost of health care and the rest of the expenditure required to make up for the time loss, judicial proceedings and other related services. Encouragingly, the current understanding of these disorders has improved over time from previous prejudices, however, there is still a significant social taboo around both SUDs and mental health conditions; this results in people not coming forward for treatment because of the discriminations that they stand to face. It is therefore for this reason that the management of these co-occurring conditions is not only a health concern but a social responsibility for the evaluation of the overall expenses incurred [5].

Comorbidity of SUDs and mental health disorders requires that the treatment of each should be done in a synchronized manner. These include baring conventional treatment approaches where SUDs and mental health disorders are treated as two different conditions thus will be dealt with separately. Combined clients' management strategies that focus on SUDs and primary course mental health disorders as part of the same system have demonstrated potential. Such approaches include such models as for instance Integrated Dual Disorder Treatment (IDDT), which uses pharmacotherapy, psychotherapy and specifically individual case management for clients diagnosed with both disorders. The other treatment approach is Cognitive Behavioural Therapy enforced with medication administration for the cognitive and behavioural issues related to substance use and mental health symptoms. Hence, the findings on the type of care point toward integrated care being more effective as people in such care have a better likelihood of getting long-term recovery, they are likely to relapse fewer times, and have better functioning. Combination is also a way to decrease the load on the health

care facilities as it would mean the administration of comprehensive care, where several aspects of disease are treated at once, which would cut down the costs and increase efficiency of care [6]. Collectively, findings relating to the connection of between SUDs and co-occurring mental health conditions remain a significant focus of scholarly research with notable impact relevance to population health and health services delivery. It is crucial to establish the role and patterns of comorbidity for these disorders, their effects on patient functioning, and strategies for their treatment, so necessary to enhance the quality of the patients' lives and to contain the social and economic costs of the illnesses [7].

## Methodology

With regard to the purpose of this study, this manuscript uses an umbrella approach to scrutinize the association between SUDs and other mental health disorders, as well as to assess the efficacy of the collaborative treatment approach for such comorbidities. RCTs, meta-analyses, longitudinal studies, and cross-sectional studies are used to increase the internal and external validity of the study to achieve the best methodological framework for the investigation of the topic. RCTs are considered as the highest level of evidence because they help reduce sources of bias and provide causal relationships. In this case, RCTs will be adopted to directly compare the effectiveness of integrated treatment strategies with non integrated ones whereby participants will be randomly assigned to the integrated treatment group or a group that will be given general non-integrated care. The nature of the literature will be more selective as meta-analyses will be used for the integration of results from various studies to capture the overall view of the effectiveness of integrated treatment models. Most of the studies will recruit participants with a shared condition and follow them over a long duration to determine the long-term impacts of the treatments and whether they are sustainable. Epidemiological cross-sectional studies will give information on current high prevalence and severity of SUDs and the association with mental health disorders to understand certain demographic and clinical profiles of the population [8].

It will be important to select the participants according to concrete inclusion criteria in order to achieve the enrolment of subjects who meet the study objectives, that is, people suffering from co-occurring SUDs and mental health conditions. The participants required for this study will be clients, twenty-five years and older, with both a SUD and a coexisting mental health disorder. These categories shall be diagnosed based on the DSM-5 criteria and other operationalised diagnostic instruments that are available. They must be preoccupied with substance use and exhibit signs of a mental disorder of a minimum severity where SUD is diagnosed; they also must have a mental health disorder of depression, anxiety, PTSD, or bipolar disorder [9].

Purposely, to reduce confounding of the observed results, all individuals having only SUD or only mental health disorder will be eliminated from the study. This exclusion criterion is quite important so that the study will be limited only to patients with SUD and patients with comorbid mental health disorder. Also, it is essential to point out that the participants with extreme cases of learning disabilities or medical conditions that would prevent the subject from undertaking the study will also be excluded. This entails factors that could have serious influences on the student's ability to think or physically, and so affect the outcome of the study [10].

To maintain the special character of the respondents a brief demographic description of the participants in the study will be recorded to align with the study type and objectives. This data will encompass age, gender, form of SUD, type of mental health disorder and severity of its manifestations. Age will be measured in years and divided into age categories as part of the analysis plan. Regarding the participants' gender, responses will be grouped under the three categories; male, female and other, which will help in determining the effectiveness of treatment based on gender. The nature of SUD will be determined by the kind of substance the patient has been depending on alcohol, opioids, stimulants, or cannabis. Likewise, the nature of the mental health condition will be classified by diagnosis which can be a depressive disorder, generalized anxiety disorder, post-traumatic stress disorder, bipolar disorder, or any other. In terms of symptoms, the intensity of SUDs and the severity of Mental Health conditions shall be rated on a valid and reliable scale, such as the: addition severity index (AS), Hamilton depression rating scale [11].

The main treatment focus that will therefore be the subject of investigation in this study shall be integrated treatment modalities. These include methods, which focus on integrated, active treatment of both SUDs and mental disorders based on the use of a unified system of therapy. Different integrated treatment approaches will be used as IDDT which comprises pharmacological intervention, psychological intervention, and even case management. IDDT is an evidence based for treating substance use disorders, emphasizing on the dual diagnosis clinical treatment that encompasses patient's mental health concerns. Another type of integrated treatment that will be discussed is the one where clients participate in CBT along with taking prescribed medications. CBT involves changing thoughts and behaviours concerning SUDs and mental illnesses; medication management guarantees adequate medication for symptom stabilization [12].

Consequently, assessment of traditional non-integrated treatment methods will also be conducted for comparison. These include categories of treatment where people with SUDs and mental health disorders receive treatment in isolation, sometimes from distinct practitioners and in different facilities. Two forms of non-integrated treatment are stand-alone substance abuse programs like detoxification and rehabilitation and other mental health services for the patient which may comprises of individual therapy or any other form of psychiatric treatment. Clients in the non-integrated treatment group shall undergo treatment for the given SUD and the comorbid mental health disorder separately without receiving, respectively, simultaneous and coordinated treatment [13].

In this study, the two main dependent variables are defined as the change in substance use and the change in mental health symptoms. Outcomes related to substance use reduction will be evaluated with the help of instruments such as ASI that quantifies the level of substance use in the medical, employment, criminal, and family and social spheres. Symptom severity will be assessed by Scales for mental health, to be more specific, the Hamilton Depression Rating Scale, which is used for the depression, Hamilton Anxiety Rating Scale used in cases of anxiety and PTSD Checklist in cases of PTSD. These scales give written or numerical information on the extent of symptoms' manifestation and progression towards recovery.

Other effective end points are enhancements in the client's quality of existence, functional status, compliance, and relapse rituals. The level of QoL shall be measured by questionnaires such as WHO QoL which, in turn, generally measures the physical, psychological, social, and environmental aspects. Self-care capacity will be assessed by questionnaires such as the Global Assessment of Functioning (GAF) scale aimed at the general psychological, social, and economic functioning of a patient. Medication compliance and therapy attendance will be assessed by the participants' self-reports as well as the clinicians who will observe callers' compliance to the recommended schedule of therapy and medication intake. Participants' patterns of substance use during follow-up assessments will be used to determine rates of relapse [14].

Assessment will be done at: baseline prior to the beginning of treatment, after the treatment, and at 6-month, 12-month, and 24-month follow up point. T0 will include the first assessments of the participants' symptoms' severity, substance use, and demographic characteristics. Instruments used to collect data/research design post-treatment assessment will focus on identifying the immediate treatment changes while follow up assessment will target identification of the treatment gains' resilience. The data will be obtained through face-to-face interviews, self-generated questionnaires, and potential participant's clinic notes [15].

Descriptive/ Inferential statistics will be used different integrated and non-integrated treatment programs to determine the best treatment. The demographics and clinical data of the study participants will be measured using descriptive analysis. Descriptive forms of analysis shall incorporate t-tests and ANOVA as tools for comparing mean values between the treatment groups. Hierarchical regression analysis will be used to determine significant correlates of treatment outcomes supplanting other influential factors. Multivariate methods also shall include moderation tests revealing the influence of the treatment type on the results depending on the patients' demographic characteristics. The analysis of the treatment effect will follow the intention-to-treat principle, which means the results will incorporate all participants enrolled in different treatment subgroups irrespective of whether they completed the treatment course and complied with the assigned regime.

## Results



Non-integrated approaches and specially integrated treatment approaches have shown major effectiveness in regard to different studies analysing SUDs and mental health disorders. An examination of such integrated models in meta-analysis presents highly impressive data that relate to the magnitude of the effect, the percentage of reduction in symptoms and the rate of abatement of the condition. Integrated treatments are the most beneficial for patients with SUD and other mental health disorders, as effect sizes demonstrate larger changes in both SUD and mental health outcomes for integrated approaches compared to non-integrated ones. Main surveys estimate that patients experienced relative symptom decrease rates; percentages mainly exceed 50%; In conditions like dual diagnosis when the patient has two SUDs and a mental disorder at the same time, outcomes worsen. Success rates of relapse are significantly lower in integrated models, a factor that goes to prove that these models are more effective in helping patients to obtain a lasting cure in contrast to non-integrated models of treatment. Comparing Integrated and Non- Integrated models some important differences have been identified concerning the results. Combined therapies prove to be more effective due to the diverse interaction between the use of substances and mental disorders. Namely, integrated approaches are more effective in certain types of SUDs and mental health disorders as they treat the root of the problem and clients' behaviour at the same time. This approach is not only for the decrease of symptoms but also results in improvement of the quality of life and functions. These analytical results also emphasize that integrated treatments are more effective than non-integrated ones since the differences are statistically significant and corroborate the better performance of the integrated treatments in difference criteria. Additional analysis of the post-treatment outcomes underlines these benefits by proving that LEARN is effective in the subgroup of patients depending on their demographic characteristics, SUDs severity, and comorbid conditions. Comprehensive treatment always shows better outcomes in different patients, including those with schizophrenia and substance use disorders, thus suggesting that the integrated care approaches can be highly effective in terms of seeking implementation in various clinical environments. Summing it up, integrated treatment practices are a revolutionized model of tackling SUDs and mental health disorders as they have demonstrated higher effectiveness, remission rates, and encompassing services targeting both the substance use and the psychiatric disorders at the same time. These studies stress the exigency for the use of the integrated health care paradigms in health facilities to enhance the health and well being of the patients with dual Dx within the health continuum.

<b>Aspect of Comparison</b>	<b>Integrated Approaches</b>	<b>Non-Integrated Approaches</b>
<b>Effect Sizes</b>	Larger, indicating significant improvements	Smaller, less pronounced improvements
<b>Percentage of Symptom Reduction</b>	Often >50%, substantial	Generally lower, <50%
<b>Remission Rates</b>	Higher, indicating sustained recovery	Lower, less sustained recovery
<b>Advantages</b>	Comprehensive care addressing both SUDs and mental health	Focus limited to either SUDs or mental health, not both
<b>Statistical Analysis</b>	Statistically significant benefits	Limited statistical significance
<b>Subgroup Analyses</b>	Effective across demographics, severity levels, conditions	Effectiveness varies, less tailored to diverse groups

## Discussion

Therefore, the results of this study are most useful in expanding the body of knowledge in the area of anxiety disorders and the effectiveness of CBT treatment, especially TC CBT and the relatively new methods of delivery such as i- CBT, MB- CBT, and ACT. The relevance of these findings lies in the fact that Traditional CBT was found effective in reducing anxiety symptoms in accordance with prior studies placing it at the root of anxiety intervention. The efficacy of Traditional CBT to bring about a significant reduction in symptoms and high rates of remission again completes the effectiveness of this therapeutic approach in regular practice [16].

On the contrary, the talk about variants born as a result of ongoing evolution reveals such aspects as advantages and positive features which define their contribution to existing processes, particularly to the treatment of anxiety. Internet-Based CBT presents as a very flexible mode of treatment delivery, which is always a plus given the patient centered approach as well as likely to attract higher patient compliance by patients who might have some form of disability that puts them off face to face therapy. MBCT has found its uses not only in treating the anxiety symptoms, but in improving the overall ways of handling stress and emotional related issues, thereby giving advantages other than the relief of symptoms. The method ACT, which is dedicated to separable psychological flexibility and acceptance, seems to appear as an essential tool especially in cases, which are hardly liable to traditional behavioural treatment.

The discussion also involves the comparison between the integrated and non-integrated treatment system. Combined treatment plans provide treatment to anxiety as well as, other associated disorders providing a holistic and efficient treatment process for the patients. It also allows for the synergy between the substance use as well as mental health treatment constituents possibly improving treatment efficacy as well as the prevention of relapse. However, the ability to combine different approaches in a patient's treatment and the coordination of the care he/she may receive among various disciplines may present the key implementational obstacles [17].

The non-integrated approaches, though giving focused attention to treat each of the condition individually may not always address adequately the interaction between anxiety and substance use. What is more, the organization of care that is not integrated often entails such potential problems as the treatment may overlap and contradict one another reducing the overall efficacy of treatment.

In light of these results, guidelines for clinical practices support the involvement of combined disorders for individuals with anxiety conditions and substance abuse. Greater emphasis should be placed on the integrated models that include both Traditional CBT and new forms as they may provide the most effective impact on patients' conditions. It also enhances the treatment of dual diagnosis patients through the application of mutual methods that focus on treating mental illnesses and substance dependence at the same time.

Additionally, the prospects of delivering individualised treatment with reference to patients' characteristics and preferences proves that the idea of the diverse and versatile utilisation of therapeutic approaches is crucial. Clinicians are urged to consider various factors of patients to be able to appropriately opt for the best treatment plan for every patient by evaluating treatment preferences, existent therapies, signs' severity, and others.

That being, there remain a few study limitations that should be reported. A number of a study's sampling techniques can be analysed including differences in the sample sizes in different studies which can increase or decrease the ability of the study findings to generalize to other populations. Differences in study practices and participants' characteristics can result in biases, for that reason, the interpretation of the comparative effectiveness outcomes should occur carefully. Also, many of the reported studies are focused on the immediacy of the effects, and therefore, while providing valuable observations, they do not shed much light on the lasting impact of these effects, and the sustainability of treatment benefits is another promising area of research in this field.

The studies for the future should focus on the comparative studies of the prolonged and integrated treatment for anxiety disorders with substance use disorders comparing the results at the later follow-up. More research on combination treatments with regard to different pharmacotherapies and additional bio-psychosocial interventions is necessary for establishing more detailed treatment

programs. However, as previous research should involve diverse samples, to reflect on the present study and the consequent generalized use of the results of analyses, in order to provide equal opportunities for control of anxiety for different segments of the population and different cultures [18].

## Conclusion

In conclusion, integrated treatment approaches for individuals with co-occurring substance use disorders (SUDs) and mental health conditions demonstrate superior efficacy compared to non-integrated methods. Models such as Integrated Dual Disorder Treatment (IDDT) and Cognitive Behavioural Therapy (CBT) combined with medication management have consistently shown significant reductions in substance use, improvements in mental health symptoms, and enhanced overall quality of life. These findings support the integration of care as a preferred approach in clinical practice, offering personalized treatment plans that address the complex interplay between SUDs and mental health issues comprehensively. While acknowledging study limitations and the need for further research, the emphasis remains on advancing integrated treatment strategies to optimize outcomes and provide effective, patient-centered care for this vulnerable population.

## References

- [1] M. Donald, "Integrated versus non-integrated management and care for clients with co-occurring mental health and substance use disorders: a qualitative systematic review of randomised controlled trials," *Social Science & Medicine*, vol. 60, no. 6, pp. 1371-1383, 2005.
- [2] M. A. P. M.S.W, "Treatment Access Barriers and Disparities Among Individuals with Co-Occurring Mental Health and Substance Use Disorders: An Integrative Literature Review," *Journal of Substance Abuse Treatment*, vol. 61, pp. 47-59, 2016.
- [3] P. M. F. Ph.D., "Co-occurring disorders in substance abuse treatment: Issues and prospects," *Journal of Substance Abuse Treatment*, vol. 34, no. 1, pp. 36-47, 2008.
- [4] C. M. Bradizza, "Relapse to alcohol and drug use among individuals diagnosed with co-occurring mental health and substance use disorders: A review," *Clinical Psychology Review*, vol. 26, no. 2, pp. 162-178, 2006.
- [5] B. G. B. Ph.D., "Young adults with co-occurring disorders: substance use disorder treatment response and outcomes," *Journal of Substance Abuse Treatment*, vol. 46, no. 4, pp. 420-428, 2014.
- [6] M. Kikkert, "Effectiveness of Integrated Dual Diagnosis Treatment (IDDT) in severe mental illness outpatients with a co-occurring substance use disorder," *Journal of Substance Abuse Treatment*, vol. 95, pp. 35-42, 2018.
- [7] M. Stacy Sterling M.P.H., "Access to Treatment for Adolescents With Substance Use and Co-Occurring Disorders: Challenges and Opportunities," *Journal of the American Academy of Child & Adolescent Psychiatry*, vol. 49, no. 7, pp. 637-646, 2010.
- [8] M. M. Ya-Fen Chan Ph.D., "Referral for substance abuse treatment and depression improvement among patients with co-occurring disorders seeking behavioral health services in primary care," *Journal of Substance Abuse Treatment*, vol. 46, no. 2, pp. 106-112, 2014.
- [9] M. Katherine E. Watkins M.D., "Association Between Quality Measures and Mortality in Individuals With Co-Occurring Mental Health and Substance Use Disorders," *Journal of Substance Abuse Treatment*, vol. 69, pp. 1-8, 2016.

- [10] C. H. Brown, "Predictors of initiation and engagement in substance abuse treatment among individuals with co-occurring serious mental illness and substance use disorders," *Addictive Behaviors*, vol. 36, no. 5, pp. 439-447, 2011.
- [11] I. T. Ph.D., "Integrated treatment programs for individuals with concurrent substance use disorders and trauma experiences: A systematic review and meta-analysis," *Journal of Substance Abuse Treatment*, vol. 42, no. 1, pp. 65-77, 2012.
- [12] P. Novak, "Behavioral health treatment utilization among individuals with co-occurring opioid use disorder and mental illness: Evidence from a national survey," *Journal of Substance Abuse Treatment*, vol. 98, pp. 47-52, 2019.
- [13] R. E. D. M. Ph.D., "A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders," *Journal of Substance Abuse Treatment*, vol. 34, no. 1, pp. 123-138, 2008.
- [14] G. Carrà, "Correlates of dependence and treatment for substance use among people with comorbid severe mental and substance use disorders: Findings from the "Psychiatric and Addictive Dual Disorder in Italy (PADDI)" Study," *Comprehensive Psychiatry*, vol. 58, pp. 152-159, 2015.
- [15] P. A. Shane, "Treatment outcomes among adolescents with substance abuse problems: the relationship between comorbidities and post-treatment substance involvement," *Evaluation and Program Planning*, vol. 26, no. 4, pp. 393-402, 2003.
- [16] H. J. G. Ph.D., "Increasing program capability to provide treatment for co-occurring substance use and mental disorders: Organizational characteristics," *Journal of Substance Abuse Treatment*, vol. 38, no. 2, pp. 160-169, 2010.
- [17] M. A. Ph.D., "Disparities in Treatment for Substance Use Disorders and Co-Occurring Disorders for Ethnic/Racial Minority Youth," *Journal of the American Academy of Child & Adolescent Psychiatry*, vol. 50, no. 1, pp. 22-31, 2011.
- [18] C. E. Grella, "Predictors of longitudinal substance use and mental health outcomes for patients in two integrated service delivery systems," *Drug and Alcohol Dependence*, vol. 110, no. 1-2, pp. 92-100, 2010.